Comparison of anti-cancer effects of platinum ribavirin and ribavirin via telomerase and Bcl-2 gene expression.
Bcl-2
Platinum ribavirin (Pt-Rb)
Ribavirin (Rb)
Telomerase
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
13
10
2023
accepted:
07
11
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
aheadofprint
Résumé
Among the common treatments for cancers, chemotherapy is widely used. One of the ways to evaluate the effectiveness of anti-cancer drugs is by checking the expression of tumor markers. Hence, this study aimed to evaluate the anti-cancer effects of the newly synthesized platinum ribavirin (Pt-Rb) compared to ribavirin (Rb) through biomarkers. In this study, cell lines were divided into four groups: groups A and B as healthy negative control group and untreated cancer group respectively. Group C and D were treated with, Rb and Pt-Rb, a novel anti-cancer drug, respectively. After evaluating LC
Identifiants
pubmed: 37975929
doi: 10.1007/s00210-023-02841-7
pii: 10.1007/s00210-023-02841-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Arvind R, Chandana SR, Borad MJ, Pennington D, Mody K, Babiker H (2021) Tumor-treating fields: a fourth modality in cancer treatment, new practice updates. Crit Rev Oncol Hematol 168:103535. https://doi.org/10.1016/j.critrevonc.2021.103535
doi: 10.1016/j.critrevonc.2021.103535
pubmed: 34808377
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr, Borden KL (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114(2):257–260. https://doi.org/10.1182/blood-2009-02-205153
doi: 10.1182/blood-2009-02-205153
pubmed: 19433856
Borden KL (2011) Targeting the oncogene eIF4E in cancer: from the bench to clinical trials. Clin Invest Med 34(6):E315. https://doi.org/10.25011/cim.v34i6.15889
doi: 10.25011/cim.v34i6.15889
pubmed: 22129918
Borden KL, Culjkovic-Kraljacic B (2010) Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma 51(10):1805–1815. https://doi.org/10.3109/10428194.2010.496506
doi: 10.3109/10428194.2010.496506
pubmed: 20629523
pmcid: 2950216
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 . Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul; 70(4):313
Cao F, Yin LX (2019) miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol 106:34–43. https://doi.org/10.1016/j.yexmp.2018.10.009
doi: 10.1016/j.yexmp.2018.10.009
pubmed: 30539797
Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, Brem H, Tyler B, Skuli N( 2019)The use of ribavirin as an anticancer therapeutic: will it go viral? Mol Cancer Ther 18(7):1185–1194. https://doi.org/10.1158/1535-7163.MCT-18-0666
Chen S, Yang C, Sun C, Sun Y, Yang Z, Cheng S, Zhuge B (2019) miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG. DNA Cell Biol 38(8):865–873. https://doi.org/10.1089/dna.2018.4529
doi: 10.1089/dna.2018.4529
pubmed: 31225740
De Vitis M, Berardinelli F, Sgura A (2018) Telomere length maintenance in cancer: at the crossroad between telomerase and alternative lengthening of telomeres (ALT). Int J Mol Sci 19(2):606. https://doi.org/10.3390/ijms19020606
doi: 10.3390/ijms19020606
pubmed: 29463031
pmcid: 5855828
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T (2021) New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med 9:20503121211034370. https://doi.org/10.1177/20503121211034366
doi: 10.1177/20503121211034366
pubmed: 34408877
pmcid: 8366192
Dratwa M, Wysoczanska B, Brankiewicz W, Stachowicz-Suhs M, Wietrzyk J, Matkowski R, Ekiert M, Szelachowska J, Maciejczyk A, Szajewski M, Baginski M, Bogunia-Kubik K (2022) Relationship between telomere length, TERT genetic variability and TERT, TP53, SP1, MYC gene co-expression in the clinicopathological profile of breast cancer. Int J Mol Sci 23(9):5164. https://doi.org/10.3390/ijms23095164
doi: 10.3390/ijms23095164
pubmed: 35563554
pmcid: 9102200
Falchetti A, Franchi A, Bordi C, Mavilia C, Masi L, Cioppi F, Recenti R, Picariello L, Marini F, Del Monte F, Ghinoi V, Martineti V, Tanini A, Brandi ML (2005) Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 20(3):410–418. https://doi.org/10.1359/JBMR.041123
doi: 10.1359/JBMR.041123
pubmed: 15746985
Furue H (2003) Chemotherapy cancer treatment during the past sixty years. Gan To Kagaku Ryoho 30(10):1404–11. Japanese
Ghosh S (2019) Cisplatin: The first metal based anticancer drug. Bioorg Chem 88:102925. https://doi.org/10.1016/j.bioorg.2019.102925
doi: 10.1016/j.bioorg.2019.102925
pubmed: 31003078
Guo XL, Ma NN, Zhou FG, Zhang L, Bu XX, Sun K, Song JR, Li R, Zhang BH, Wu MC, Wei LX (2009) Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep 22(3):549–556. https://doi.org/10.3892/or_00000470
doi: 10.3892/or_00000470
pubmed: 19639202
Hall C, Troutman SM, Price DK, Figg WD, Kang MH (2013) Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. Clin Genitourin Cancer 11(1):10–19. https://doi.org/10.1016/j.clgc.2012.09.002
doi: 10.1016/j.clgc.2012.09.002
pubmed: 23083798
Jeng KS, Sheen IS, Jeng WJ (2011) Azidothymidine treatment of hepatocellular carcinoma in rats: an in vivo study of telomerase inhibition. Hepatogastroenterology 58(112):2091–2096. https://doi.org/10.5754/hge11087
doi: 10.5754/hge11087
pubmed: 22024081
Khodapasand E, Jafarzadeh N, Farrokhi F, Kamalidehghan B, Houshmand M (2015) Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? Iran Biomed J 19(2):69–75. https://doi.org/10.6091/ibj.1366.2015
doi: 10.6091/ibj.1366.2015
pubmed: 25864810
pmcid: 4412916
Low IC, Kang J, Pervaiz S (2011) Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 15(12):2975–2987. https://doi.org/10.1089/ars.2010.3851
doi: 10.1089/ars.2010.3851
pubmed: 21574773
Lyu SY, Choi SH, Park WB (2002) Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res 25(1):93–101. https://doi.org/10.1007/BF02975269
doi: 10.1007/BF02975269
pubmed: 11885700
Manganelli M, Grossi I, Corsi J, D’Agostino VG, Jurikova K, Cusanelli E, Molfino S, Portolani N, Salvi A, De Petro G (2022) Expression of cellular and extracellular TERRA, TERC and TERT in hepatocellular carcinoma. Int J Mol Sci 23(11):6183. https://doi.org/10.3390/ijms23116183
doi: 10.3390/ijms23116183
pubmed: 35682861
pmcid: 9181112
Maring S, Elsayad K, Stenner M, Rudack C, Haverkamp U, Rehkämper J, Wardelmann E, Eich HT (2018) Efficacy of carboplatin/paclitaxel-based radiochemotherapy in locally advanced squamous cell carcinoma of head and neck. Oncol Res Treat 41(12):736–743. https://doi.org/10.1159/000494031
doi: 10.1159/000494031
pubmed: 30419553
Mattiuzzi C, Lippi G (2019) Current cancer epidemiology. J Epidemiol Glob Health 9(4):217-222. https://doi.org/10.2991/jegh.k.191008.001
Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM (2012) A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 31(1–2):247–268. https://doi.org/10.1007/s10555-011-9342-8
doi: 10.1007/s10555-011-9342-8
pubmed: 22179983
Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S, Saya H (1998) Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 16(7):933–943. https://doi.org/10.1038/sj.onc.1201602
doi: 10.1038/sj.onc.1201602
pubmed: 9484785
Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J (2021) Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol 74(5):1155-1166. https://doi.org/10.1016/j.jhep.2020.11.052 . Epub 2020 Dec 15. Erratum in: J Hepatol. 2022 May; 76(5):1242-1243
Niture SK, Jaiswal AK (2012) Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287(13):9873–9886. https://doi.org/10.1074/jbc.M111.312694
doi: 10.1074/jbc.M111.312694
pubmed: 22275372
pmcid: 3323009
Roake CM, Artandi SE (2020) Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol 21(7):384–397. https://doi.org/10.1038/s41580-020-0234-z
doi: 10.1038/s41580-020-0234-z
pubmed: 32242127
pmcid: 7377944
Romaniuk-Drapała A, Totoń E, Konieczna N, Machnik M, Barczak W, Kowal D, Kopczyński P, Kaczmarek M, Rubiś B (2021) hTERT downregulation attenuates resistance to DOX, impairs FAK-mediated adhesion, and leads to autophagy induction in breast cancer cells. Cells 10(4):867. https://doi.org/10.3390/cells10040867
doi: 10.3390/cells10040867
pubmed: 33920284
pmcid: 8068966
Roy PS, Saikia BJ (2016) Cancer and cure: a critical analysis. Indian J Cancer 53(3):441–442. https://doi.org/10.4103/0019-509X.200658
doi: 10.4103/0019-509X.200658
pubmed: 28244479
Sabokrouh A, Vaisi-Raygani A, Goodarzi MT, Khatami S, Taghizadeh-Jahed M, Shahabadi N, Lakpour N, Shakiba Y (2015) Comparison between platinum-azidothymidine and azidothymidine effects on Bcl-2 and telomerase gene expression in rats with hepatocellular carcinoma. Avicenna J Med Biotechnol 7(2):50–56
pubmed: 26140181
pmcid: 4483314
Sandin S, Rhodes D (2014) Telomerase structure. Curr Opin Struct Biol 25(100):104–110. https://doi.org/10.1016/j.sbi.2014.02.003
doi: 10.1016/j.sbi.2014.02.003
pubmed: 24704747
pmcid: 4045397
Shahabadi N, Mirzaei kalar Z, Moghadam NH (2012) DNA interaction studies of a platinum (II) complex containing an antiviral drug, ribavirin: the effect of metal on DNA binding. Spectrochim Acta A Mol Biomol Spectrosc 96:723-8. https://doi.org/10.1016/j.saa.2012.07.020
Sharma R, Singh VJ, Chawla PA (2022) Advancements in the use of platinum complexes as anticancer agents. Anticancer Agents Med Chem 22(5):821–835. https://doi.org/10.2174/1871520621666210805150705
doi: 10.2174/1871520621666210805150705
pubmed: 34353272
Shu XL, Fan CB, Long B, Zhou X, Wang Y (2016) The anti-cancer effects of cisplatin on hepatic cancer are associated with modulation of miRNA-21 and miRNA-122 expression. Eur Rev Med Pharmacol Sci 20(21):4459–4465
pubmed: 27874954
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. https://doi.org/10.3322/caac.21166
doi: 10.3322/caac.21166
pubmed: 23335087
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Tan J, Ye J, Song M, Zhou M, Hu Y (2018) Ribavirin augments doxorubicin’s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol 32(1). https://doi.org/10.1002/jbt.22007
Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B (2022) Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol 435:115829. https://doi.org/10.1016/j.taap.2021.115829
doi: 10.1016/j.taap.2021.115829
pubmed: 34919946
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R (2020) Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 86:102019. https://doi.org/10.1016/j.ctrv.2020.102019
doi: 10.1016/j.ctrv.2020.102019
pubmed: 32251926
pmcid: 7272286
Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3(11):697–707. https://doi.org/10.1046/j.1365-2443.1998.00223.x
doi: 10.1046/j.1365-2443.1998.00223.x
pubmed: 9990505
Xu M, Tao Z, Wang S, Jiang Y, Qu M (2019) Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma. Biochem Biophys Res Commun 512(4):902–907. https://doi.org/10.1016/j.bbrc.2019.03.118
doi: 10.1016/j.bbrc.2019.03.118
pubmed: 30929914
Yang H, Xu S, Tang L, Gong J, Fang H, Wei J, Su D (2022) Targeting of non-apoptotic cancer cell death mechanisms by quercetin: implications in cancer therapy. Front Pharmacol 13:1043056. https://doi.org/10.3389/fphar.2022.1043056
doi: 10.3389/fphar.2022.1043056
pubmed: 36467088
pmcid: 9708708
Zhang Z, Yu L, Dai G, Xia K, Liu G, Song Q, Tao C, Gao T, Guo W (2017) Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells. Sci Rep 7(1):7070. https://doi.org/10.1038/s41598-017-07204-w
doi: 10.1038/s41598-017-07204-w
pubmed: 28765565
pmcid: 5539325
Zhao C, Wang M, Liu Y, Liang Y, Han L, Chen C (2018) Effects of the combination of As2O3 and AZT on proliferation inhibition and apoptosis induction of hepatoma HepG2 cells following silencing of Egr-1. Onco Targets Ther 11:3293–3301. https://doi.org/10.2147/OTT.S155169
doi: 10.2147/OTT.S155169
pubmed: 29910624
pmcid: 5987793
Zvereva MI, Shcherbakova DM, Dontsova OA (2010) Telomerase: structure, functions, and activity regulation. Biochemistry (Mosc) 75(13):1563–1583. https://doi.org/10.1134/s0006297910130055
doi: 10.1134/s0006297910130055
pubmed: 21417995